KMT2A::AFDN t(6;11) (aka KMT2A::MLLT4 or MLL::AF6)
Quantitative RQ-PCR detection of KMT2A::AFDN fusion transcripts from t(6;11) involving the 11q23 KMT2A locus.
KMT2A::AFF1 t(4;11) (aka MLL::AF4)
Quantitative RQ-PCR detection of KMT2A::AFF1 fusion transcripts from t(4;11), associated with poor prognosis in B-ALL.
KMT2A::MLLT10 (MLL::AF10) t(10;11)
Quantitative RQ-PCR detection of KMT2A::MLLT10 fusion transcripts from the t(10;11) translocation.
KMT2A::MLLT11 (MLL::AF1) t(1;11)
Quantitative RQ-PCR detection of KMT2A::MLLT11 fusion transcripts from the t(1;11) translocation.
KMT2A::MLLT3 (MLL::AF9) t(9;11)
Quantitative RQ-PCR detection of KMT2A::MLLT3 fusion transcripts from the t(9;11) translocation.
KMT2A::MLLT1 / KMT2A::ELL t(11;19)
Quantitative RQ-PCR detection of KMT2A::MLLT1 (MLL::ENL) and KMT2A::ELL (MLL::ELL) fusion transcripts from t(11;19) in ALL and AML.
TCF3::PBX1 (E2A::PBX1) t(1;19)
Quantitative RQ-PCR detection of TCF3::PBX1 (E2A::PBX1) fusion from t(1;19) for ALL diagnosis and minimal residual disease monitoring.
ETV6::RUNX1 t(12;21)
Quantitative RQ-PCR detection of the t(12;21) ETV6::RUNX1 (TEL::AML1) fusion, associated with favorable prognosis in ALL.
ABL1 Tyrosine Kinase Domain Mutation Analysis
Sanger sequencing of ABL1 tyrosine kinase domain to detect imatinib resistance mutations in BCR::ABL1-positive CML, ALL, and AML.
BCR::ABL1 Qualitative Breakpoints p190 vs p210
Qualitative RQ-PCR identification of BCR::ABL1 fusion transcript breakpoint type (major p210 vs minor p190) for diagnosis of CML, ALL, and AML.